Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrickTM design, serum-free virus production and microcarrier-based cultivation of CV-1 cells by Liu, S et al.
Establishing elements of a
synthetic biology platform for
Vaccinia virus production:
BioBrickTM design, serum-free
virus production and
microcarrier-based cultivation
of CV-1 cells
Shuchang Liu a,b, Ludmila Ruban a, Yaohe Wang b, Yuhong Zhou a,
Darren N. Nesbeth a,*
aDepartment of Biochemical Engineering, University College London, Bernard Katz Building, London WC1E 6BT,
UK
bBarts Cancer Institute, Queen Mary University of London, London EC1 M 6BQ, UK
*Corresponding author.
E-mail address: d.nesbeth@ucl.ac.uk (D.N. Nesbeth).
Abstract
Vaccinia virus (VACV) is an established vector for vaccination and is beginning to
prove effective as an oncolytic agent. Industrial production of VACV stands to
benefit in future from advances made by synthetic biology in genome engineering
and standardisation. The CV-1 cell line can be used for VACV propagation and has
been used extensively with the CRISPR/Cas9 system for making precise edits of
the VACV genome. Here we take first steps toward establishing a scalable
synthetic biology platform for VACV production with CV-1 cells featuring
standardised biological tools and serum free cell cultivation. We propose a new
BioBrickTM plasmid backbone format for inserting transgenes into VACV. We
then test the performance of CV-1 cells in propagation of a conventional
recombinant Lister strain VACV, VACVL-15 RFP, in a serum-free process. CV-1
cells grown in 5% foetal bovine serum (FBS) Dulbecco’s Modified Eagle Medium
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(DMEM) were adapted to growth in OptiPRO and VP-SFM brands of serum-free
media. Specific growth rates of 0.047 h−1 and 0.044 h−1 were observed for cells
adapted to OptiPRO and VP-SFM respectively, compared to 0.035 h−1 in 5% FBS
DMEM. Cells adapted to OptiPRO and to 5% FBS DMEM achieved recovery
ratios of over 96%, an indication of their robustness to cryopreservation. Cells
adapted to VP-SFM showed a recovery ratio of 82%. Virus productivity in static
culture, measured as plaque forming units (PFU) per propagator cell, was 75 PFU/
cell for cells in 5% FBS DMEM. VP-SFM and OptiPRO adaptation increased
VACV production to 150 PFU/cell and 350 PFU/cell respectively. Boosted PFU/
cell from OptiPRO-adapted cells persisted when 5% FBS DMEM or OptiPRO
medium was observed during the infection step and when titre was measured using
cells adapted to 5% FBS DMEM or OptiPRO medium. Finally, OptiPRO-adapted
CV-1 cells were successfully cultivated using Cytodex-1 microcarriers to inform
future scale up studies.
Keywords: Biological sciences, Biochemistry, Bioengineering, Cell biology,
Microbiology History
1. Introduction
Vaccinia virus (VACV) is an enveloped, brick-shaped particle typically 300 × 240
× 120 nm containing a double stranded DNA genome which, for the Lister strain
(Garcel et al., 2007), is 189.4 kilobase-pairs (kb) in size, encoding up to 201 open
reading frames (ORFs). VACV is arguably one of the most effective
biotechnological tools in history by dint of the fact human antibodies raised
against VACV tend also to recognise smallpox epitopes. VACV was used to
eradicate smallpox via a global vaccination programme carried out by the World
Health Organization (WHO) between 1966 and 1980 (Fenner et al., 1988).
VACV has also been used as a molecular biology tool to effect high-level
transgene expression in mammalian cells, due in part to its ≈25 kb capacity for
accommodating recombinant DNA (Mackett and Smith, 1986; Hruby, 1990; Guse
et al., 2011). Molecular biology techniques developed in this area have also
enabled construction of a wide range of recombinant VACV vaccines in which
selected epitopes or payloads are defined by recombinant DNA.
Recombinant VACV has been developed as an effective live vaccine against viral,
bacterial and oncological diseases (Hruby, 1990; Lee et al., 1994; Timiryasova
et al., 1999; Zhang et al., 2007), due to its ability to elicit vigorous antibody and T-
cell mediated responses. Hiley et al. (2010) and Tysome et al. (2011) have also
demonstrated the effectiveness of recombinant Lister strain VACV in targeting
hypoxic tumours in human head and neck cancer.
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Mass production of VACV for smallpox eradication was achieved by harvesting
virus from lesions brought about by infection of live animals (Fenner et al., 1988).
However, this method brought significant risk of contamination with microbiolog-
ical agents and was superseded by viral propagation in embryonated hen eggs
(EAEMP 2002). Monath et al. (2004) investigated the use of MRC-5 cells to
produce the New York City Board of Health (NYCBH) VACV strain for a Phase I
clinical trial as a smallpox vaccine. As a human diploid cell line, MRC-5 has a
finite in vitro life span that limits capacity for long-term cultivation . Large-scale
VACV production using diploid cell lines can be difficult as such cells typically do
not grow well on microcarriers (Barrett et al., 2009).
At laboratory-scale, scale-out strategies, such as roller bottles, T-flasks and the
NuncTM Cell FactoryTM, are commonly used to cultivate adherent cells for
propagation of VACV. However, methods that can be scaled up, as opposed to
scaled out, are the ideal solution for increasing the level of production,
predictability and affordability for widespread application of VACV-based
therapies. Toward this aim Bleckwenn et al. (2005) used HeLa S3 cells grown
on microcarriers, at 1.5L scale, in a hollow fibre perfusion bioreactor setup to
propagate VACV.
Viral vaccine production in media supplemented with bovine serum has been
discouraged by regulatory authorities such as the Food and Drug Administration
(FDA), brings high variability between serum batches and can lead to variations in
product yield and quality. Undefined components in serum may also provide a route
for adventitious agent contamination. Bioprocesses that are serum-free and animal
derived component free (ADCF) are now sought in order to reduce the contamination
risk, ease the downstream processing artefacts and promote robustness and reliability
for the production of VACV. Previous attempts to grow CV-1 cells in serum-free
media (Steimer et al., 1981) replaced serum with other animal-derived products so
did not remove routes for adventitious agent contamination.
Synthetic biology aims to render biological phenomena easier to engineer (Ye and
Fussenegger 2014). An inevitable consequence of this aim is that biology becomes
easier to manufacture. When applied to VACV production, and its exploitation in
areas such as gene therapy and oncotherapeutics, synthetic biology offers the
prospect of rapid design and assembly of viral payloads using interoperable tools,
such as BioBrickTM-formatted plasmids (Shetty et al., 2008), compatible with
repositories containing thousands of components. Synthetic DNA is now also
being used to construct large segments of eukaryotic genomes (Dymond et al.,
2011) and construction of human artificial chromosomes (Kononenko et al., 2015)
is now an established approach in gene therapy research.
Vero cells are commonly used for VACV propagation and have been investigated
in terms of their VACV production during cultivation in serum-free media
Article No~e00238
3 http://dx.doi.org/10.1016/j.heliyon.2017.e00238
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
(Mayrhofer et al., 2009), and on microcarriers (Monath et al., 2004). The CV-1 cell
line is more often used for VACV titration (Schweneker et al., 2012) but recently
multiple reports have been published demonstrating the use of the Cas9 nuclease/
clustered regularly interspaced short palindromic repeats (Cas9/CRISPR) system to
edit VACV genomes during CV-1 based virus propagation (Yuan et al., 2015a;
Yuan et al., 2015b; Yuan et al., 2016a; Yuan et al., 2016b). The Cas9/CRISPR
system enables precise, multiple edits of a genome to be made in parallel and has
had a huge impact in the field of synthetic biology and beyond.
Because Cas9/CRISPR tools for VACV have been established in CV-1 cells, in
this study we take the following first steps toward establishing a CV-1-based
synthetic biology platform for VACV production: i) we propose a BioBrickTM-
formatted plasmid backbone for VACV genome engineering, ii) we retrofit VACV
production in CV-1 cells from serum-containing media to serum-free media, iii) for
serum-free adapted CV-1 cells, we measure growth performance and viral
productivity during T flask cultivation and finally iv) we measure growth of serum-
free adapted CV-1 cells in a microcarrier-based cultivation platform.
2. Material and methods
2.1. Cell cultivation
CV-1 cells, product CCL-70TM from American Type Culture Collection (ATCC),
were grown in High Glucose Dulbecco’s Modification of Eagle’s Medium
(DMEM) from PAA Laboratories (Pasching, Austria), supplemented with 5% v/v
foetal bovine serum (FBS) from batches A10409-1728 and A15112-2026 for three
passages prior to this study. Cells were passaged twice weekly in T flasks and
seeded at 1 × 104 cells/cm2 for growth in 5% FBS DMEM and serum-free
OptiPRO and 2 × 104 cells/cm2 for growth in serum-free VP-SFM medium.
Serum-free media was supplemented with GlutaMAX to 4 mM and detached by
treatment with TrypLE Select. All materials were sourced from Life Technologies,
New York, USA, unless otherwise stated.
2.2. Cell banking and revival
Cells adapted to growth in 5% FBS DMEM were cryopreserved in 90% FBS plus
10% v/v dimethyl sulfoxide (DMSO) from Sigma-Aldrich (Ayrshire, UK). Cells
adapted to growth in serum-free media were frozen in a v/v mixture of; 45% fresh
growth medium, 15% 2 day, 15% 3 day and 15% 4 day conditioned medium plus
10% DMSO and 0.1% v/v methylcellulose (Sigma). Cells were suspended in the
cryopreservation medium at 3–5 × 106 cells/mL and transferred to 2 mL screw cap
cryopreservation tubes (Eppendorf Ltd, Stevenage, UK) for storage in the liquid
phase of a liquid nitrogen Dewar (Part No. 9902130, Statebourne Cryogenics, Tyne
& Wear, UK). For revival, cryopreservation tubes were removed from liquid
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nitrogen and thawed in a SUB14 water bath at 37 °C (Grant Instruments,
Cambridge, UK). Upon thawing, cells suspended in cryopreservation solution were
diluted to a volume of 8 mL and centrifuged at 1300 rpm for 3 min. The
supernatant was withdrawn and cell pellet was resuspended in 8 mL pre-warmed
OptiPRO and transferred to a T 25 flask and incubated at 37 °C, 5% CO2 in an
MCO-19AIC incubator (Sanyo, Gunma, Japan).
2.3. Counting cells cultivated using T flasks
Cells were detached from flask surfaces using standard trypsin treatment. Total
cells in suspension were then counted using a TC10TM Automated Cell Counter
(Bio-Rad, Hercules, USA) according to manufacturer’s instructions (document
PN10016620 Rev B). Total viable cell counts in suspension were performed using
standard trypan blue dye exclusion. Cells were stained with 0.4% trypan blue
(#T8154, Sigma-Aldrich, Aryshire, UK) and counted using an Improved Neubauer
haemocytometer (Hawksley, Lancing, UK) within three minutes of staining.
2.4. Adaptation to serum free media
Cells were grown in 10% FBS DMEM to a density of 1.3 × 105 cells/cm2 in a T-25
flask (3.25 × 106 cells total). Cells were then harvested into a total volume of 8 mL
growth media mix, containing, for each round of adaptation; 6 mL, 4 mL, 2 mL,
0.8 mL and finally zero mL 10% FBS DMEM made up to 8 mL with serum-free
media before further passaging. OptiPRO or VP-SFM brands of serum-free
medium were used, as indicated in Fig. 2.
2.5. Cell growth kinetics in T flasks
Average cell growth rate (cells/cm2/day) was calculated using Eq. (1),
Cell growth ¼ CH  CS
D
(1)
-where CH is total cell density (cells/cm
2) at harvest; CS is the total cell density
(cells/cm2) at seeding and D is culture duration (days). Cell Recovery Ratio
(CRR) under complete serum free conditions was calculated using Eq. (2).
CRR% ¼ 100% NF
NT
× 100% (2)
-where NF is total number of detached cells 24 h post seeding; NT is total
number of cells seeded (cells/cm2). Specific growth rate, μ (h−1) was based on
Eq. (3).
μt ¼ lnxn
x0
(3)
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Where x0 is starting total cell concentration per mL; t is the time of sampling in
hours; x is total cell concentration per mL after t hours. A plot of ln x versus
time (see Eq. (1)) gives a straight-line plot with μ as the slope. Cell doubling
time, DT (hours) was calculated using Eq. (4), where μmax is the maximum
specific growth rate during the exponential phase, hour−1.
DT ¼ ln2
μmax
(4)
2.6. Virus propagation
A single virus stock was used throughout this work. The Lister VACV, VACVL-
15 RFP, has been propagated historically at Queen Mary University of London and
encodes a red fluorescent protein (RFP) as reporter. A titre of 6.68 × 108 PFU/mL
was determined for this stock using the procedures described below and with CV-1
cells used for titration. Aliquots of virus for infection were diluted with the
required volume of growth media. Virus solutions were added drop wise to cells at
a density of 3–5 × 105 cells/well in a 6-well plate at a multiplicity of infection
(MOI) of 0.1. After the indicated time period, infected ‘propagator’ cells were
harvested using a cell scraper for virus release by cell disruption.
2.7. Virus release from cells
Suspensions of cells infected for virus propagation were frozen in a −80 °C freezer
for 30 min, thawed in a 37 °C water bath for 4 min and vortexed for 10 seconds.
This freeze-thaw-vortex cycle was repeated three times and the resultant disruptate
containing cell debris and released virus particles used for virus titration with no
further purification.
2.8. Virus infection of target cells for titration
Median tissue culture infective dose (TCID50) was determined using CV-1 cells as
indicator cells. Disruptates, containing cell debris and viruses, were serially diluted
in 96-well plates containing cells adapted to, and grown in, 5% FBS DMEM unless
otherwise stated. Cytopathic effect (CPE) was scored by light microscopy six days
post infection. The Reed-Muench procedure (1938) was used to calculate TCID50
values, which were converted to PFU/cell using Eq. (5).
PFU=Cell ¼ 0:69
TCID50value ×Vs×NI
(5)
-where Vs is the volume of sample used to infect the first row of the 96-well
titration plates, mL; NI is number of cells at infection.
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2.9. Growth on microcarriers of CV-1 cells adapted to OptiPRO
medium
2.9.1. Pre-treatment of vessels and microcarriers
Cultivation of OptiPRO-adapted CV-1 cells adhered to Cytodex-1 microcarriers
(GE Healthcare, Westborough, USA) was performed using a Techne MCS-104L
250 mL spinner flask setup (Bibby Scientific Ltd, Staffordshire, UK). All
procedures were performed in a Level 1 laminar flow biological safety cabinet
(BSC) unless otherwise stated. Spinner flasks were first prepared for use by
siliconisation of the flask interior surface and impellers using Sigmacote (SL2,
Sigma-Aldrich, USA) in accordance with manufacturer’s instructions. When the
siliconisation procedure was complete the impeller system was assembled within
the 250 mL spinner flask and autoclaved using a cycle of 20 min at 121 °C.
A 0.5L pyrex Duran bottle was also coated with silicon using the Sigmacote and
following manufacturer’s instructions. Briefly, 100 mL of Sigmacote were poured
into to the 0.5L pyrex Duran bottle which was swirled until all the interior surface
received a covering of Sigmacote. Remaining Sigmacote was decanted and the
bottle was autoclaved, dried in a fume hood overnight then rinsed with Milli-Q
water to remove any siliconisation by-products before use.
The required mass of Cytodex-1 microcarriers (17-0448-01, GE Healthcare,
Sweden) was added to the siliconised Pyrex Duran bottle. For every gram of dry
microcarriers 100 mL of pH 7.4 PBS, free of calcium and magnesium ions (Life
Technologies, Paisley, UK), was added. The bottle was left to stand over night to
achieve complete swelling and hydration of the microcarriers. The next day the
PBS used to hydrate the microcarriers was gently decanted and replaced with 50
mL fresh PBS for every gram of wet microcarriers. The microcarrier slurry was
then sterilized by autoclaving (121 °C, 20 min). Prior to use, the sterilized
microcarriers were allowed to cool and settle. Upon cooling the supernatant was
gently decanted and replaced with 50 mL fresh OptiPRO medium for every gram
of wet microcarriers. This OptiPRO/microcarrier slurry was allowed to settle and
the OptiPRO supernatant was gently decanted then replaced with 100 mL fresh
OptiPRO for every gram of wet microcarriers.
2.9.2. Mixing cells and microcarriers
30 mL of the microcarrier/media slurry was transferred to the spinner flask. 70 mL
of a suspension of OptiPRO-adapted CV-1 cells in OptiPRO was then added to the
spinner flask to achieve a microcarrier concentration of 3 g/L and a cell
concentration of 3.4 × 105 cells/mL, corresponding to 26 cells/microcarrier. The
spinner flask was then placed on the MCS-104L stirrer device inside an MCO-
19AIC incubator (Sanyo, Gunma, Japan) at 37 °C and 5% CO2. The mixture of
Article No~e00238
7 http://dx.doi.org/10.1016/j.heliyon.2017.e00238
2405-8440/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
cells and microcarriers was subjected to intermittent agitation at 30 RPM for 30
seconds every 30 min for the first two days of cultivation after which continuous
30 RPM agitation was used for the third day and then 35 RPM for the remainder of
the cultivation experiment. Approximately 70% of the volume of culture medium
was replaced with fresh OptiPRO every 24 h by terminating agitation; allowing
microcarriers to settle decanting supernatant and adding fresh OptiPRO.
2.9.3. Removing CV-1 cell samples during microcarrier-based
cultivation
The MCS-104L stirrer device was switched off and transferred, with the spinner
flask, from the incubator to the BSC. The stirrer was set to agitate the spinner flask
at 60 RPM and the cap from one side-arm port of the spinner flask was removed to
allow withdrawal of a 0.2 mL sample from the culture. The MCS-104L stirrer
device was then switched off and the entire setup returned to the incubator where
incubation and agitation were resumed.
2.9.4. Counting CV-1 cells during cultivation using microcarriers
Samples taken as above were typically transferred to a 1.5 mL Eppendorf tube and
washed with 1 mL PBS. Microcarriers were allowed to settle and 1 ml supernatant
was gently decanted; then a further 1 mL PBS wash performed. After the final
decanting of supernatant 0.2 mL aqueous crystal violet solution (0.1% w/v Crystal
Violet, 0.1 M citric acid, 0.1% v/v Triton X-100) was added to the microcarriers
slurry and the mixed by pipetting up and down 25 times before the Eppendorf tube
was transferred to an incubator set at 37 °C/5% CO2 for 1.5 h. This treatment
causes cells to lyse and release stained nuclei. Typically the solution was diluted by
addition of PBS. Released nuclei were counted using an Improved Neubauer
haemocytometer (1080346, Heinz Herenz Medizinalbedarf GmbH, Hamburg,
Germany) as an indicator of cell numbers.
3. Results and discussion
3.1. Proposal for a BioBrickTM-based VACV plasmid tools
The VACV genome is conventionally edited within mammalian cells by parallel
viral infection and transfection with a plasmid. The plasmid typically encodes a
transgene intended for insertion into the VACV genome is flanked by sequences
identical to a VACV locus. Homologous recombination within the mammalian cell
then directs insertion of the transgene at the intended VACV genome location
(Fig. 1). Typically the locus encoding the ORF for thymidine kinase (TK) is used
to target insertion of transgenes (Byrd and Hruby, 2004) as its disruption does not
compromise virus replication in cells commonly used for virus propagation
(Fig. 1). Plasmids designed for this purpose often feature a multiple cloning site
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flanked upstream and downstream by regions of homology with the VACV TK
gene. However, such multiple cloning sites tend to be designed without
consideration of any standards for DNA assembly.
The Registry of Standard Biological Parts is widely used by synthetic biologists
and uses the BioBrickTM standard for plasmids and their assembly by ligation. The
Registry, run by staff of the International Genetically Engineered Machines
(iGEM) Foundation (Boston, USA), consists of a large plasmid library (Mu ̈ller &
Arndt, 2012) curated by users. All BioBrickTM formatted plasmids are inter-
compatible so any plasmid designed in the BioBrickTM format is automatically
compatible with the entire BioBrickTM registry.
For BioBrickTM compatibility a given DNA segment need only be flanked upstream
by a defined sequence motif encoding, in order, EcoRI, NotI and XbaI restriction sites
and downstream by, in order, SpeI, NotI and PstI sites (Canton et al., 2008; Shetty
et al., 2011). These flanking sequences are known as the BioBrickTM prefix and
suffix. BioBrickTM tools for virus design have been developed previously, such as
BBa_K404129 that encodes a transgene expression cassette designed to be
encapsidated by adeno-associated virus. Here we have designed a new BioBrickTM
plasmid backbone, BBa_J140000, which features the BioBrickTM prefix and suffix
flanked by 5′ and 3′ end regions of the VACV TK ORF. Any BioBrickTM of interest
[(Fig._1)TD$FIG]
E X S PTK5 TK3
CmpR
b) BBa_J14nnnn
TKc) VACV genome
d) modified VACV genome
E X S PTK5 TK3
CmpR
a) BBa_J140000
BOI
E X S PTK5 BOI TK3
Fig. 1. Design of a BioBrickTM-formatted Vaccinia DNA tool. a) Overview of BBa_J140000, a
proposed BioBrickTM plasmid backbone for VACV genome editing. The plasmid incorporates a
chloroamphenicol resistance selection marker (CmpR) and the BioBrickTM prefix: Eco RI (E), Xba I
(X), and suffix: Spe I (S), Pst I (P). Not I sites are omitted for graphical brevity. The BioBrickTM
cloning site is flanked by 5′ and 3′ ends of the TK locus for homologous recombination. b) A
BioBrickTM of interest (BOI) can be cloned into BBa_J140000 using standard BioBrickTM assembly,
resulting in a new plasmid, BBa_J14nnnn. c) Parallel cell infection with unmodified VACV and
transfection with BBa_J14nnnn can then result in recombination for insertion of the BOI into the
genome of replicating, progeny VACV. d) This insertion will result in a new, recombinant VACV.
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(BOI) can be inserted into this region of BBa_J140000 by ligation then subsequently
into the VACV genome by co-transfection and recombination (Fig. 1).
3.2. Adaptation of CV-1 cells to serum free growth media
CV-1 is a continuous cell line derived from Cercopithecus aethiops African green
monkey kidneys by Jensen (1964). It is susceptible to several viruses including
VACV and has been widely used for virus titration (Cho et al., 1970; Hiley et al.,
2010). CV-1 cells were grown in a rich medium, 10% FBS DMEM, before
stepwise adaptation to growth in the VP-SFM and OptiPRO brands of serum-free
medium. The serum content (v/v) of the growth mediummix used during each round
of adaptation was lowered to 7.5%, 2.5%, 1% and finally 0%. Fig. 2 shows the average
growth rates observed when cells were first challenged with the decreased serum
content media mix. Average CV-1 cell growth rate in 10% FBS DMEM was 2.93 ±
0.54 × 104 cells/cm2/day. Average growth rates in 7.5% and 5% FBSmediamixes, for
both VP-SFM andOptiPRO, were increased compared to 10%FBSDMEM. Only 0%
serum, pure VP-SFM or OptiPRO, resulted in initial growth rates lower than that for
10% FBS DMEM, with 1.97 × 104 cells/cm2/day and 1.29 × 104 cells/cm2/day
respectively. Cells were then grown in VP-SFM or OptiPRO for another four
passages before being considered as fully adapted to serum-free media.
3.3. Growth profiles of CV-1 cells adapted to serum-free media
Cells adapted to 5% FBS DMEM, VP-SFM and OptiPRO were seeded at 5 × 104
cells/25 cm2 in T-25 flask and cell densities measured every 24 h for 350 h to
[(Fig._2)TD$FIG]
G
ro
w
t h
R
at
e
x1
04
ce
ll s
/ c
m
2 /d
ay
0
1
2
8
7
6
5
4
3
10 8 7 6 5 4 3 2 1 09
% FBS
Fig. 2. Average growth rates of CV-1 cells during stepwise adaption to serum-free media. Starting at
10% FBS DMEM (square) cells were harvested and re-plated in mixtures of serum-containing and
serum-free medium to give the serially decreasing overall serum concentration indicated by the X-axis.
VP-SFM (triangles) or OptiPRO SFM (circles) brands of serum free medium were used. Growth rates
were determined as detailed in Methods.
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observe lag, exponential and stationary phases (Fig. 3) and determine growth rate
(Table 1). For cells adapted to 5% FBS DMEM (Fig. 3A), total cell numbers
decreased over the first 24 h post-seeding. Growth increased after this with a
specific growth rate of 0.035 h−1 observed, corresponding to a doubling time of
20.1 h. This is comparable to the doubling time of 22 h reported by Hagedorn et al.
(1985) for CV-1 cells grown in medium with 5% v/v foetal calf serum (FCS). Cell
growth slowed after 168 h, at a saturation density of 4.52 × 106 cells/25 cm2.
Saturation density of adherent cells on a solid surface is a potential indicator of
microcarrier growth performance.
Cells adapted to VP-SFM (Fig. 3B), decreased rapidly in number over the first 95 h
post-seeding, with viability as low as 4.9%. Cells then entered exponential growth,
achieving 90% viability and a specific growth rate of 0.044 h−1 (15.9 h doubling
time). Cells entered stationary phase 235 h post-seeding with saturation density of
2.15 × 106 cells/25 cm2.
[(Fig._3)TD$FIG]
Fig. 3. Growth of CV-1 cells adapted to serum-free media. Cells adapted to, and grown in, A) 5% FBS
DMEM (squares), B) VP-SFM (triangles) and C) OptiPRO (circles) were seeded into T-25 flasks at the
density indicated and their growth (closed symbols) and viability (open symbols) followed over 350 h.
Total cells were detached by trypsinisation, counted and reseeded in fresh media at each time point,
with 1–5% of material discarded after cell counting and viability assessment. Dashed line indicates the
linear regression of cell growth during exponential phase used to calculate growth rates provided in
Table 1. Error bars indicate standard deviation over n = 2 biological repeats.
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Growth of cells adapted to OptiPRO (Fig. 3C) lagged over the first 67 h post-
seeding then grew exponentially, with a specific growth rate of 0.047 h−1 (14.8 h
doubling time). These cells reached stationary phase at 192 h post-seeding, at a
saturation density of 3.84 × 106 cells/25 cm2. Notably, a significant decrease in
viability was observed 24 h post-seeding. This increased to >90% at 67 h,
remained above 90% until 200 (160) hours then declined to <60% at 354 h post-
seeding.
Compared to cells adapted to grow in 5% FBS DMEM, cells adapted to VP-SFM
and OptiPRO had lower saturation densities and significant drops either in cell
number or viability in the first 96 h post-seeding. The absence of specific growth
factors (Todaro et al., 1965; Vogel et al., 1980) or nutrients from certain serum-
free media formulations may result in reduced shear resistance in mammalian cells
(EL-Ensahsy et al., 2009). This could explain the extended lag phase growth of
cells adapted to VP-SFM and OptiPRO compared to those adapted to 5% FBS
DMEM (Fig. 3). VP-SFM and OptiPRO-adapted cells may have required a longer
time period to recover from shear experienced over multiple rounds of detachment,
resuspension and re-seeding during adaptation (Fig. 2).
3.4. CV-1 cell robustness to cryopreservation
Stable and reliable recovery from cryopreservation is a critical attribute of
mammalian cells used for industrial production of biotherapeutics. Recovery ratio
provides an indication of the effectiveness of a given formulation of cryopreservant
media for storing cells under liquid nitrogen. Cells adapted to growth in 5% FBS
DMEM, VP-SFM and OptiPRO were resuspended in cryopreservant media, as
detailed in the Methods section above, containing methylcellulose as a protective
agent only for CV-1 cells previously adapted to VP-SFM and OptiPRO
(Waymouth and Vamum, 1976). After storage in liquid nitrogen for six months
Table 1. Performance of cells adapted to serum-containing and serum-free media
types. Summary of performance data for cells adapted to growth in the different
media types. Column 1 shows recovery from cryopreservation (recovery ratio).
Column 2 provided growth rates of cells after adaptation to the indicated media
type.
1 2
Medium used for cell
adaptation and growth
Recovery Ratio
(% ± STD)
Specific Growth Rate
μ (h−1)
VP-SFM 82.10 ± 3.59 0.044
OptiPRO SFM 97.31 ± 0.34 0.047
5%FBS DMEM 97.15 ± 0.72 0.035
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cells were revived and recovery ratios determined (Table 1). Recovery ratios of
≈97% were measured for cells grown in, and adapted to, both OptiPRO and 5%
FBS DMEM. Cells adapted to VP-SFM had the lowest recovery ratio of ≈82%.
3.5. Vaccinia virus production by CV-1 cells adapted to grow in
serum-free media
For production of VACV strain TSI-GSD-241 using MRC-5 cells for propagation,
Wu et al. (2005) reported virus productivity of 77 PFU/cell when the cells were
grown in 20% FBS DMEM and infected at an MOI of 0.1. We used a recombinant
Lister strain VACV, VACVL-15 RFP, encoding a red fluorescent protein
expression cassette payload. At an MOI of 0.1 we infected CV-1 cells (as
‘propagators’) adapted to, and cultivated in, 5% FBS DMEM, VP-SFM or
OptiPRO. Infected cells were incubated at 37 °C with 5% CO2 for 24, 48 and 72 h
post-infection after which virus was released and virus titre measured (Fig. 4) by
infection of CV-1 cells adapted to, and cultivated in, 5% FBS DMEM as ‘targets’
cells. At 72 h post infection ‘propagator’ cells adapted to growth in OptiPRO
achieved a titre of 352 PFU/cell, 4.6 fold higher than the titre achieved by cells
adapted to 5% FBS DMEM and 2.6 fold higher than the titre achieved by cells
adapted to VP-SFM.
3.6. Influence of media type and cell provenance on viral titre
performance
It is not evident from Fig. 4 whether the enhanced titre performance of OptiPRO-
adapted cells results from OptiPRO favouring virus infection events or OptiPRO
exerting a selective pressure that favours CV-1 cells capable of high virus
[(Fig._4)TD$FIG]
Fig. 4. Viral productivity of CV-1 cells adapted for growth in serum free media. Viral titre productivity
of CV-1 cells adapted for growth in VP-SFM (open bar), OptiPRO (black bars) and 5% FBS DMEM
(striped bars). Cells at 80–95% confluence were infected with VACVL-15 RFP at MOI = 0.1 and virus
liberated for titration at indicated times post-infection. Error bars indicate standard deviation over n = 3
biological repeats.
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productivity. Furthermore, compatibility with a notional synthetic biology
production platform for VACV manufacture would require multiple iterations of
entirely serum-free propagation.
As such we repeated the OptiPRO, 72 h post-infection harvest time experiment of
Fig. 4 alongside two comparator experiments in an attempt to determine both the
likely causative factors for the increased titre observed in Fig. 4 and the relative
efficiency of an entirely serum-free round of propagation. Table 2 summarises our
approach; cells adapted for growth in OptiPRO were grown to 95% confluence
then washed twice with PBS before immersion either again in OptiPRO (Fig. 5A
and C) or 5% FBS DMEM (Fig. 5B), immediately prior to infection. For titration,
OptiPRO-adapted cells in the presence of OptiPRO (Fig. 5A) and 5% FBS DMEM-
adapted cells in the presence of 5% FBS DMEM (Fig. 5B and C) were used as
‘targets’ for titre measurement.
Experiment C (Table 2) is a straight repeat of the conditions used in Fig. 4 (data in
black bars, harvest 72 h post-infection) so the resultant titre was set as the 100%
level for comparison with Experiments A and B (see Table 2, Fig. 5A and B). If the
presence of OptiPRO media enhances VACV infection of CV-1 cells, then
Table 2. Dissecting effect of growth medium and cell-adaptation on viral infection and production.
Experiment setup A: CV-1 cells adapted to growth in OptiPRO were washed in PBS, re-immersed in
OptiPRO and infected with VACV at MOI = 0.1. 72 h post-infection, progeny virus from these cells was
used to infect CV-1 cells adapted to growth in OptiPRO, in the presence of OptiPRO. Experiment setup B:
CV-1 cells adapted to growth in OptiPRO were washed in PBS, immersed in 5% FBS DMEM and infected
with VACV at MOI = 0.1. 72 h post-infection, progeny virus from these cells was used to infect CV-1 cells
adapted to growth in 5% FBS DMEM, in the presence of 5% FBS DMEM. Experiment setup C: CV-1 cells
adapted to growth in OptiPRO were washed in PBS, re-immersed in OptiPRO and infected with VACV at
MOI = 0.1. 72 h post-infection, progeny virus from these cells was used to infect CV-1 cells adapted to
growth in 5% FBS DMEM, in the presence of 5% FBS DMEM. Data generated from these experiments
were plotted in Fig. 5. *Propagator: cells that are infected with virus for the purpose of harvesting virus
particles from those cells. **Target: cells that have been infected with virus in order to establish a TCID50 as
an indication of the titre of the virus solution used to infect the cells.
Experiment A B C
Propagator cell* Cells adapted to growth in
OptiPRO
Cells adapted to growth in Opti-
PRO
Cells adapted to growth in Opti-
PRO
Media present during Propagator
cell infection
OptiPRO 5% FBS DMEM OptiPRO
Target cell** Cells adapted to growth in
OptiPRO
Cells adapted to growth in 5%
FBS DMEM
Cells adapted to growth in 5%
FBS DMEM
Media present during Target cell
infection
OptiPRO 5% FBS DMEM 5% FBS DMEM
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Experiment A could be expected to increase the titre achieved by Experiment C
(see Table 2, Fig. 5A and C). This is not the case, with Experiment A yielding at
best the same titre performance as Experiment C. If the presence of 5% DMEM
enhances VACV infection of CV-1 cells, then Experiment B could be expected to
increase the titre achieved by Experiment C (see Table 2, Fig. 5B and C). This is
not the case, with Experiment B yielding at best the same titre performance as
Experiment C.
Taken together, observations from Figs. 4 and 5 are consistent with the enhanced
titre observed for OptiPRO-adapted cells being due to the process of adaptation to
OptiPRO media also exerting a post-infection phenotype of increased virus
productivity. They also indicate that entirely serum-free rounds of VACV
propagation, such as those likely to define industrial synthetic biology platforms,
yield comparable titre performance to serum-containing processes and so are
feasible.
3.7. CV-1 cell cultivation using OptiPRO and microcarriers
We sought to determine if CV-1 cells adapted to OptiPRO could be cultivated
using microcarriers (Fig. 6). We attempted cultivation using Cytodex-1 micro-
carriers and a Techne MCS-104L 250 mL spinner flask setup (Bibby Scientific
Ltd, Staffordshire, UK) in which microcarrier suspensions were agitated by
bulb–shaped glass impellers driven directly by a magnetic base. OptiPRO-adapted
CV-1 cells were able to grow on micocarriers when approximately 70% of
[(Fig._5)TD$FIG]
Fig. 5. Influence of media and cell type on viral titre performance. As set out in Table 2, CV-1 cells
were washed in PBS and re-immersed either in OptiPRO or 5% FBS DMEM, infected with VACV at
MOI = 0.1 and 72 h post-infection progeny virus used to infect cells adapted to growth in OptiPRO in
the presence of OptiPRO (Experimental setup A) or 5% FBS DMEM (Experimental setup B), or cells
adapted to growth in 5% FBS DMEM in the presence of 5% FBS DMEM (Experimental setup C). Error
bars indicate standard deviation over n = 3 biological repeats. As Experimental setup C was a repeat of
the experiment performed to generate the data in Fig. 4 (72 virus harvest 72 h post-infection), the titre
achieved with Experimental setup C was set as the 100% level.
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OptiPRO mediumwas changed daily and showed reduced growth when the
OptiPRO made was unchanged over 270 h of cultivation (Fig. 6).
In the case of T-flask cultivation, VACV propagation involves two significant
factors: virus number and cell numbers, which are summarised by the MOI. By
contrast microcarrier-based VACV propagation presents three major factors;
viruses, cells and microcarriers, and as such represents a complex investigation to
identify productivity optima, such as those reported by Monath et al. (2004) for
production of VACV from Vero cells grown using microcarriers and Bleckwernn
et al. at (2005) for VACV production from HeLa cells. Such an investigation falls
outside the scope of this study, which is to indicate the broad feasibility of the steps
likely to define a future synthetic biology platform for VACV production.
4. Conclusions
We have proposed a new BioBrickTM plasmid backbone, BBa_J140000, which in
effect makes every BioBrickTM in the Registry of Standard Biological Parts
available for insertion into the TK locus of VACV without the need for bespoke
cloning strategies. CV-1 cells adapted for growth in OptiPRO serum free medium
exhibited elevated titre performance when grown using static culture. Mechanisms
underlying the elevated titre are unclear but may result from selective pressure
exerted by the adaptation process acting also to select for an unintended phenotype.
These adapted CV-1 cells also showed promising growth characteristics on
Cytodex-1 microcarriers.
[(Fig._6)TD$FIG]
Fig. 6. Cultivation of CV-1 cells adapted to OptiPRO media on microcarriers. Cells adapted for growth
in OptiPRO were mixed with Cytodex-1 microcarriers at a starting ratio of 26:1 in 100 mL OptiPRO
and agitated at 30–35 RPM over the indicated period. Cell concentrations were plotted for cultivation in
which either 70% of the OptiPRO was changed every 24 h (black circles) or OptiPRO was unchanged
throughout (open squares). Error bars indicate standard deviation over n = 3 biological repeats, P < 0.05.
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Overall these results are consistent with the assertion that a standardised, serum-
free, microcarrier-based synthetic biology platform for production of VACV is
feasible. Cultivation in suspensions is inherently more scalable than cultivation on
planar surfaces so further scale up of the platform proposed here should be
investigated. Future work should include an investigation of the optimal conditions
for VACV production from CV-1 cells grown on microcarriers, including the ratio
of infecting virus to cells and microcarriers. Characterisation of virus quality
should also be performed to assess factors such as the percentage of total virus
particles that are plaque-forming as opposed to inactive.
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